StockAxis

Anupam Rasayan India Ltd

Chemicals

Little Masters

CMP
Rs. 951.50
Rating:
Buy
April 12, 2023

Stock Info

BSE
543275
NSE
ANURAS
Bloomberg
ANURAS:IN
Reuters
-
Sector
Chemicals
Face Value (Rs)
10
Equity Capital (Rs cr)
100
Mkt Cap (Rs cr)
10,147.35
52w H/L (Rs)
954.75 - 546.75
Avg Daily Vol (BSE+NSE)
285,155

Shareholding Pattern

(as on 31-Dec)
%
Promoter
60.96
FIIs
8.19
DIIs
6.18
Public & Others
24.67
Source: Ace equity, StockAxis Research

Price performance

Return (%)
1m
3m
12m
Absolute
28.37
38.05
11.37
Sensex
3.30
0.09
2.02
Source: Ace equity, StockAxis Research

Indexed Stock Performance

Anupam Rasayan India Ltd Sensex
Anupam Rasayan India Ltd
Source: Ace equity, StockAxis Research

Poised for Growth

Company Profile

Anupam Rasayan (ARIL) is one of the leading companies engaged in the custom synthesis and manufacturing of specialty chemicals in India. It has two distinct business verticals: (i) life science-related specialty chemicals, comprising products related to agrochemicals, personal care, and pharmaceuticals; and (ii) other specialty chemicals, comprising specialty pigments and dyes, polymer additives. We believe that its ability to meet stringent quality and technical specifications and customizations, undertake a large number of complex chemical reactions and automated manufacturing capabilities, develop in-house innovative processes along with strong technical competencies and R&D capabilities, and have a transparent cost model has enabled it to act as a complete one-stop solution for process innovation and its ability to meet stringent quality and technical specifications and customizations, undertake a large number of complex chemical reactions and automated manufacturing capabilities, develop in-house innovative processes along with strong technical competencies and R&D capabilities, and have a transparent cost model has enabled it to act as a complete one-stop solution for process innovation and the development of specialty chemicals for multinational companies in a cost-efficient manner. They are also one of the leading companies in manufacturing products using continuous and flow chemistry technology on a commercial scale in India.

Further, they have a dedicated in-house R&D facility and a pilot plant located at Sachin Unit 6, which are equipped with laboratories engaged in process development, process innovation, new chemical screening, and engineering, which assist them in pursuing efficiencies from the initial conceptualization up to the commercialization of a product. Its R&D team has successfully carried out multi-step synthesis and scale up for several new molecules in the area of life sciences-related specialty chemicals and other specialty chemicals, and as a result, it has expanded its commercialized product portfolio from 25 products in fiscal 2018 to 48 products in Fy22.

Investment Arguments

Strong pipeline of LOI/Contracts

The company has a strong pipeline of LOI/Contracts worth INR 26,200 Mn, which provide revenue visibility for the next 5 years. On March 23, 2023, ARIL signed Letter of Intent  (LOI) worth revenue of $120 million (Rs 984 crore) for the next 6 years with one of the leading Japanese Chemical company to supply new age advance intermediate for life science active ingredient. Sales realization for this molecule will be one of the highest for the company. This product is being manufactured for the first time in India, and it is in line with the government's make in India policy. 

Capital Expenditure to Drive Growth

ARIL has been incurring capex to add new products to its portfolio over the last three years, resulting in growth in its installed capacity to 27,200 metric tonnes in FY22 from 12,000 metric tonnes in FY18, and product offerings increasing to 48 from 25 over the same period. The company is likely to incur further capex of INR 2,500 million over the next one-to-two years, with full revenue contribution from the incremental capex to be realized in FY25-FY26. ARIL is looking at 670 crore in capex in Gujarat to set up new plants. This will be a brownfield  expansion. The company has invested INR 100 crores until 9MFY23 out of its total planned capex of INR 170–180 crores in FY23. Further capex of INR 300 Cr and INR 250 Cr will be incurred during FY24 and FY25, respectively. The capex will primarily be in relation to the letter of intent and the contracts worth INR 26,200 million signed in FY22 for five years, and would lead to an expansion of capacities at the company’s Sachin and Jhagadia plants. Furthermore, growth capex will also be incurred in FY25 and FY26, with an aim to add more fluorination-based products, among others. Management is seeing strong demand across the portfolio.

A foray into fluorination products is a key growth driver.

Anupam is commercializing fluorination products in Q4 with a potential market opportunity of over USD 200 million. As key RM supply security from Tanfac has been established, Anupam is in a sweet spot. Accordingly, the company expects to launch 5 molecules in Q4FY23 itself. ARIL identified 14 molecules to be launched in 12–18 months.

Acquisition of Tanfac Industries Limited

ARIL also acquired a 25.79% stake and management control in Tanfac Industries Limited, a specialty fluoride chemicals manufacturer, for around INR 1,500 million. The acquisition is aimed at improving the backward integration of fluorinating agents such as potassium fluoride and hydrogen fluoride, which are the key raw materials in fluorination chemistry, and reducing the company's import dependence on China. Furthermore, with the ready availability of these two agents, ARIL plans to add more fluorination derivatives to its existing product portfolio.

Demand green shoots from European customers due to energy crisis: The company is benefitting from the European energy crisis as it has signed two new contracts worth INR 1,000 Mn with an European agrochemical company.

Contracts with cost pass-through provide cash flow visibility.

Around half of the company’s FY22 revenue was from contracts, ranging from two to five years. These contracts allow complete cost pass-through either on a semi-annual or annual basis, or according to the management, the company is yet to see a contract not renewed. In addition, for a majority of the products, ARIL is either the sole or the primary supplier to its customer. Consequently, the company enjoys long-term revenue and cash-flow visibility, along with relatively stable margins, despite the significant volatility inherent to the industry. Long-term visibility is further supported by the fact that many of the contracted customers are large and well-reputed MNCs, including Sumitomo Chemical Company Ltd., Syngenta, UPL, and Adama, among others. Long-term visibility of cash flow further helps the company in effectively managing the capex cycle.

Q3FY23 Financial Performance

Anupam Rasayan reported steady earnings for the quarter ended Q3 FY23. On a consolidated basis, Anupam Rasayan India Ltd. (ARIL) reported revenue of Rs. 382.7 cr in Q3FY23, which grew by +43.8% YoY and 0.9% QoQ. YoY growth is not comparable to the effect of Tanfac’s acquisition given during the quarter. Revenue contribution from Life Science—speciality chemicals and other specialty chemicals was 82% and 18%, respectively, compared to 90% and 10% in Q2 FY23. The growth is coming on three factors. The portfolio mix, the growth in volumes and price and the growth across geographies.  The volume growth has contributed about 55-60 per cent to the overall revenue growth, while the balance has come from price. EBITDA increased by 35.8% year on year to Rs.109.1 crore, but decreased by 2.2% quarter on quarter. EBITDA margin stood at 26.6% (-158 bps year over year and -36 bps QoQ). The margin dropped slightly on a sequential basis on account of lower absorption of fixed overheads as one unit was shut down due to the fire incident during the quarter. Net profit was reported at Rs. 54.4 crore (+43.5% year on year and 13.9% quarter on quarter). The improvement in net profit on a sequential basis was on account of higher other income compared to the last quarter.

The management has lowered its revenue guidance from 30%+ to 25%+, and EBITDA margin is expected to be in the range of 26-28% on a conservative basis, with upside potential owing to a change in product mix towards value-added products.

Key Risks & Concerns

  • ARIL faces a customer concentration risk as it derives 85-87% of its revenues from its top 10 customers.
  • Risks to the CSM industry include: cancellation or deferral of contract orders; regulatory issues that can hamper the execution of contracts and the flow of new orders; and the inability to recover increases in input costs and opex in contracts.
  • Susceptibility to volatility in forex rates and economic downturns: The company derives over 50% of its revenue from exports to Europe, North America, and other regions, and imports 15-20% of its requirements, thus benefiting from a partial hedge. Though open positions are hedged through forward contracts, operations remain susceptible to sharp changes in forex rates. Any economic downturn that impacts demand poses an additional challenge.

Outlook & Valuation

We like Anupam Rasayan because its focus on fluorination, which is high growth chemistry. Demand is strong across product portfolio. Strong pipeline of products provides revenue visibility. We believe portfolio mix will improve margins in coming quarters.

At CMP of Rs. 941, the stock is currently trading at 24.85x FY25E (EPS – Rs.37.86) and hence, we recommend a BUY on the stock

Consolidated Financial Statements